RxDoctor Payments DataLook up a doctor →

Nitin Desai, MD

Internal Medicine · Fayetteville, NCNPI 1245202696

Payments from drug & device makers

$6,422,025in general payments, 2019–2025

Across 610 payments — averaging $10,528 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$3.6M
  • Bavarian Nordic A/s$723K
  • Novavax Inc$624K
  • Janssen Research & Development, LLC$466K
  • Pfizer$364K
  • Merck$358K
  • plus $250K from 19 others

What the payments were for

  • Food & beverage$1,786100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,422,025 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$97,460
Medicare patients
205
Services billed
1,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$116,810
TrulicityDulaglutide71$82,432
JanuviaSitagliptin Phosphate41$48,487
RybelsusSemaglutide25$37,797
JardianceEmpagliflozin33$19,782
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,856
EliquisApixaban26$15,869
MyrbetriqMirabegron18$8,797
SymbicortBudesonide/Formoterol Fumarate20$4,603
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,471
Atorvastatin Calcium382$3,257
Levemir FlexpenInsulin Detemir15$3,018
Omeprazole213$2,369
Venlafaxine Hcl ErVenlafaxine Hcl28$2,303
Albuterol Sulfate HfaAlbuterol Sulfate66$2,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$252$154,607107 claims
Lilly USA, LLCTrulicity$80$82,43271 claims
MerckJanuvia$358,455$48,48741 claims
Boehringer IngelheimJardiance$35$19,78233 claims
GSKTrelegy Ellipta$20,352$16,85626 claims
PfizerEliquis$364,480$15,86926 claims
AstraZenecaSymbicort$41,554$4,60320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →